Skip to content
DataLookout
Menu

NCT07945353

Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

2-year Progression-Free Survival (PFS) Rate
Timeframe: 2 years after randomization

Secondary (7)

Radiotherapy Omission Rate
2-year Event-Free Survival (EFS) Rate
Objective Response Rate (ORR)
Complete Response (CR) Rate
Local Recurrence Rate at the Irradiated Site
Show 2 moreShow less
Incidence of Adverse Events
Quality of life questionnaire(EORTC QLQ-C30)

Arms and interventions

Orelabrutinib + 4 Gy ISRTExperimental

Participants will receive oral orelabrutinib for 12 weeks, followed by 4 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 2 fractions. Radiotherapy will be initiated within 4 weeks after completion of orelabrutinib. Response will be assessed after treatment, and additional local radiotherapy or salvage treatment may be administered according to the predefined response-based management strategy.

24 Gy ISRTActive comparator

Participants will receive 24 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 12 fractions. Radiotherapy will be initiated within 4 weeks after randomization. Patients with inadequate response may receive salvage treatment at the investigator's discretion.

Drugs: Orelabrutinib

Radiation: 4 Gy Involved-Site Radiotherapy (ISRT), 24 Gy Involved-Site Radiotherapy (ISRT)

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China